These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 22307992)

  • 1. Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties.
    Coleman PJ; Schreier JD; Cox CD; Breslin MJ; Whitman DB; Bogusky MJ; McGaughey GB; Bednar RA; Lemaire W; Doran SM; Fox SV; Garson SL; Gotter AL; Harrell CM; Reiss DR; Cabalu TD; Cui D; Prueksaritanont T; Stevens J; Tannenbaum PL; Ball RG; Stellabott J; Young SD; Hartman GD; Winrow CJ; Renger JJ
    ChemMedChem; 2012 Mar; 7(3):415-24, 337. PubMed ID: 22307992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia.
    Cox CD; Breslin MJ; Whitman DB; Schreier JD; McGaughey GB; Bogusky MJ; Roecker AJ; Mercer SP; Bednar RA; Lemaire W; Bruno JG; Reiss DR; Harrell CM; Murphy KL; Garson SL; Doran SM; Prueksaritanont T; Anderson WB; Tang C; Roller S; Cabalu TD; Cui D; Hartman GD; Young SD; Koblan KS; Winrow CJ; Renger JJ; Coleman PJ
    J Med Chem; 2010 Jul; 53(14):5320-32. PubMed ID: 20565075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia.
    Winrow CJ; Gotter AL; Cox CD; Tannenbaum PL; Garson SL; Doran SM; Breslin MJ; Schreier JD; Fox SV; Harrell CM; Stevens J; Reiss DR; Cui D; Coleman PJ; Renger JJ
    Neuropharmacology; 2012 Feb; 62(2):978-87. PubMed ID: 22019562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders.
    Di Fabio R; Pellacani A; Faedo S; Roth A; Piccoli L; Gerrard P; Porter RA; Johnson CN; Thewlis K; Donati D; Stasi L; Spada S; Stemp G; Nash D; Branch C; Kindon L; Massagrande M; Poffe A; Braggio S; Chiarparin E; Marchioro C; Ratti E; Corsi M
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5562-7. PubMed ID: 21831639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognition.
    Uslaner JM; Tye SJ; Eddins DM; Wang X; Fox SV; Savitz AT; Binns J; Cannon CE; Garson SL; Yao L; Hodgson R; Stevens J; Bowlby MR; Tannenbaum PL; Brunner J; Mcdonald TP; Gotter AL; Kuduk SD; Coleman PJ; Winrow CJ; Renger JJ
    Sci Transl Med; 2013 Apr; 5(179):179ra44. PubMed ID: 23552372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a potent, CNS-penetrant orexin receptor antagonist based on an n,n-disubstituted-1,4-diazepane scaffold that promotes sleep in rats.
    Whitman DB; Cox CD; Breslin MJ; Brashear KM; Schreier JD; Bogusky MJ; Bednar RA; Lemaire W; Bruno JG; Hartman GD; Reiss DR; Harrell CM; Kraus RL; Li Y; Garson SL; Doran SM; Prueksaritanont T; Li C; Winrow CJ; Koblan KS; Renger JJ; Coleman PJ
    ChemMedChem; 2009 Jul; 4(7):1069-74. PubMed ID: 19418500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of 5''-chloro-N-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2':5',3''-terpyridine-3'-carboxamide (MK-1064): a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia.
    Roecker AJ; Mercer SP; Schreier JD; Cox CD; Fraley ME; Steen JT; Lemaire W; Bruno JG; Harrell CM; Garson SL; Gotter AL; Fox SV; Stevens J; Tannenbaum PL; Prueksaritanont T; Cabalu TD; Cui D; Stellabott J; Hartman GD; Young SD; Winrow CJ; Renger JJ; Coleman PJ
    ChemMedChem; 2014 Feb; 9(2):311-22. PubMed ID: 24376006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of dual orexin receptor antagonists (DORAs) for the treatment of insomnia.
    Coleman PJ; Cox CD; Roecker AJ
    Curr Top Med Chem; 2011; 11(6):696-725. PubMed ID: 21261591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Almorexant, a dual orexin receptor antagonist for the treatment of insomnia.
    Neubauer DN
    Curr Opin Investig Drugs; 2010 Jan; 11(1):101-10. PubMed ID: 20047164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orexin receptor antagonists: a review of promising compounds patented since 2006.
    Coleman PJ; Renger JJ
    Expert Opin Ther Pat; 2010 Mar; 20(3):307-24. PubMed ID: 20180618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulators.
    Gotter AL; Garson SL; Stevens J; Munden RL; Fox SV; Tannenbaum PL; Yao L; Kuduk SD; McDonald T; Uslaner JM; Tye SJ; Coleman PJ; Winrow CJ; Renger JJ
    BMC Neurosci; 2014 Sep; 15():109. PubMed ID: 25242351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin receptor function, nomenclature and pharmacology.
    Gotter AL; Webber AL; Coleman PJ; Renger JJ; Winrow CJ
    Pharmacol Rev; 2012 Jul; 64(3):389-420. PubMed ID: 22759794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of conformationally constrained N,N-disubstituted 1,4-diazepanes as potent orexin receptor antagonists.
    Coleman PJ; Schreier JD; McGaughey GB; Bogusky MJ; Cox CD; Hartman GD; Ball RG; Harrell CM; Reiss DR; Prueksaritanont T; Winrow CJ; Renger JJ
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2311-5. PubMed ID: 20207138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.
    Herring WJ; Snyder E; Budd K; Hutzelmann J; Snavely D; Liu K; Lines C; Roth T; Michelson D
    Neurology; 2012 Dec; 79(23):2265-74. PubMed ID: 23197752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
    Hoyer D; Jacobson LH
    Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment and prevention of various therapeutic conditions using OX receptor antagonistic activity (WO2012081692).
    Christopher JA; Congreve MS
    Expert Opin Ther Pat; 2013 Feb; 23(2):273-7. PubMed ID: 23282091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia.
    Bonaventure P; Shelton J; Yun S; Nepomuceno D; Sutton S; Aluisio L; Fraser I; Lord B; Shoblock J; Welty N; Chaplan SR; Aguilar Z; Halter R; Ndifor A; Koudriakova T; Rizzolio M; Letavic M; Carruthers NI; Lovenberg T; Dugovic C
    J Pharmacol Exp Ther; 2015 Sep; 354(3):471-82. PubMed ID: 26177655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist.
    Winrow CJ; Gotter AL; Cox CD; Doran SM; Tannenbaum PL; Breslin MJ; Garson SL; Fox SV; Harrell CM; Stevens J; Reiss DR; Cui D; Coleman PJ; Renger JJ
    J Neurogenet; 2011 Mar; 25(1-2):52-61. PubMed ID: 21473737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of MK-8133: An orexin-2 selective receptor antagonist with favorable development properties.
    Kuduk SD; Skudlarek JW; DiMarco CN; Bruno JG; Pausch MH; O'Brien JA; Cabalu TD; Stevens J; Brunner J; Tannenbaum PL; Garson SL; Savitz AT; Harrell CM; Gotter AL; Winrow CJ; Renger JJ; Coleman PJ
    Bioorg Med Chem Lett; 2015 Jun; 25(12):2488-92. PubMed ID: 25981685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.
    Roecker AJ; Cox CD; Coleman PJ
    J Med Chem; 2016 Jan; 59(2):504-30. PubMed ID: 26317591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.